CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We have now added a new section called the "Assay History List" to the "At A Gla...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...